Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
MAO-B Inhibitor
MAO-B-IN-53 is a selective inhibitor of human monoamine oxidase B (hMAO-B) with an IC50 of 0.066 μM. This compound demonstrates mixed reversible inhibition and binding stability at the hMAO-B active site, while displaying a high selectivity for hMAO-B over hMAO-A. Due to its neuroprotective properties, MAO-B-IN-53 has been shown to mitigate 6-OHDA-induced cellular damage with minimal neurotoxicity in neuroblastoma cells, making it a valuable reagent for research into Parkinson's disease. -
Monoamine Oxidase Inhibitor
Fluoroclorgyline is a potent monoamine oxidase inhibitor that demonstrates an IC50 of 39 nM. This compound effectively modulates monoamine levels, making it a valuable tool for studying neurotransmitter dynamics and related disorders. Its application in neuropharmacology and mental health research provides insight into the biochemical pathways involved in mood regulation and neurodegenerative diseases. -
Monoamine Oxidase Inhibitor
Pimprinine is a potent monoamine oxidase inhibitor that has been isolated from fermented broths. This compound exhibits significant antioxidative properties and demonstrates anticonvulsant activity. Research indicates that Pimprinine effectively inhibits tremorine-induced tremors and produces analgesic effects in murine models, making it valuable for further investigation in neuropharmacological studies. -
MAO-B Inhibitor
PSB-1434 is a selective inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 of 1.59 nM. This compound demonstrates greater than 6000-fold selectivity for MAO-B over MAO-A. PSB-1434 is primarily utilized in research applications focused on neurological disorders, making it a valuable reagent for studies involving dopaminergic signaling and neurodegenerative diseases. -
MAO-B inhibitor
Illudinine is a sesquiterpenoid alkaloid that acts as a selective inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 value of 18.3 μM. This compound is valuable for investigating the biochemical pathways associated with neurological diseases, making it a potential tool for the study of neurodegenerative disorders and related therapeutic approaches. -
MAO-B Inhibitor
MAO-B-IN-42 is a selective and reversible inhibitor of monoamine oxidase-B (MAO-B), exhibiting an IC50 value of 0.184 μM. By inhibiting the oxidative deamination of monoamines, MAO-B-IN-42 helps preserve neurotransmitter levels. This compound is valuable for research in Parkinson's disease and related neurological conditions. -
hMAO-B Inhibitor
hMAO-B-IN-3 is a potent inhibitor of human monoamine oxidase B (hMAO-B) with an IC50 value of 47.4 nM. This compound exhibits favorable agent-like properties and a broad safety margin, making it an excellent candidate for lead optimization. Its activity suggests potential applications in the development of multitarget-directed ligands for neurodegenerative diseases and related research areas. -
Insecticides/Monoamine Oxidase Inhibitors
Insecticidal Agent 32 is a potent insecticide and monoamine oxidase inhibitor that targets the enzyme responsible for the degradation of neurotransmitters in insects. This compound exhibits significant biological activity by disrupting normal neurological functions, leading to increased toxicity in target insect species. It is valuable in research applications focusing on insect neurobiology and the development of innovative pest control strategies. -
MAO-A/B Inhibitor
WAY-620147 is an N-(2-morpholinoethyl)nicotinamide derivative that acts as a selective inhibitor of monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). Demonstrating inhibitory potency with IC50 values of 26 μM for MAO-A and 55 μM for MAO-B, this compound is valuable for exploring the roles of these enzymes in neurochemistry and the treatment of mood disorders. Research applications include studying monoamine metabolism and the potential development of antidepressant therapies. -
Monoamine Oxidase-A Inhibitor
BW1370U87 is a selective inhibitor of monoamine oxidase-A (MAO-A), a key enzyme involved in the catabolism of monoamines. This compound exhibits anti-depressant activity, making it a valuable tool for research focused on mood disorders and neuropharmacology. Its ability to modulate neurotransmitter levels positions BW1370U87 as a candidate for studying therapeutic strategies targeting depressive and anxiety-related conditions. -
MAO Inhibitor
6-Acetonyl-N-methyldihydrodecarine is a natural alkaloid recognized for its function as a monoamine oxidase (MAO) inhibitor. This compound exhibits significant biological activity by modulating the levels of monoamines, which are crucial neurotransmitters in various physiological processes. It serves as a valuable reagent in research applications targeting neuropharmacology and the study of mood disorders. -
MAO-B Inhibitor
NW-1172 free base is a selective inhibitor of monoamine oxidase B (MAO-B). It demonstrates significant biological activity by increasing levels of neurotransmitters, making it useful in research applications related to neurodegenerative disorders and mental health. Studies indicate that the (R) isomer is more effective than the (S) isomer, showing superior performance in cognitive tasks and enhanced affinity for the MAO-B target, thus providing insights into its potential therapeutic benefits. -
MAO-B Inhibitor
PSB-1410 is a selective and competitive inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 value of 0.23 nM for human MAO-B and 1.01 nM for rat MAO-B. Its potent inhibition of MAO-B activity makes PSB-1410 valuable for research into neurodegenerative diseases, mood disorders, and other conditions associated with altered monoamine levels. This compound is suitable for studies focusing on the modulation of neurotransmitter metabolism and the role of MAO-B in various biological processes. -
MAO-B Inhibitor
SZV-558 is a selective inhibitor of monoamine oxidase B (MAO-B), demonstrating IC50 values of 50 nM for rat and 60 nM for human MAO-B. This compound has potential applications in the study of Parkinson's disease models, providing insights into neurochemical pathways and therapeutic strategies for this neurodegenerative disorder. Its potency makes it a valuable tool for research focused on MAO-B-related mechanisms in neurodegeneration. -
MAO-B Inhibitor
NW-1772 (methanesulfonate) is a selective inhibitor of monoamine oxidase B (MAO-B), demonstrating potent reversible inhibition. It is characterized by its ability to rapidly penetrate the blood-brain barrier, short-acting effects, and minimal toxicity in vitro. Additionally, NW-1772 shows limited inhibition of certain cytochrome P450 enzymes, making it a valuable tool for investigating neurodegenerative diseases and exploring the biochemical pathways related to neurotransmitter metabolism. -
Monoamine Oxidase Inhibitor
Lilly 51641 is a selective and orally active inhibitor of Type A monoamine oxidase, influencing neurotransmitter metabolism. This compound exhibits potential for investigation in neurological disorders, particularly depression and schizophrenia, by modulating levels of norepinephrine and serotonin. Its targeted mechanism makes it a valuable tool for research into the underlying biochemical pathways of these conditions. -
hMAO-A Inhibitor
hMAO-A-IN-1 is a selective inhibitor of human monoamine oxidase A (hMAO-A), exhibiting a potency with an IC50 of 90 nM. This compound is suitable for investigating the role of hMAO-A in neuropsychiatric disorders, particularly in the context of anxiety and depression research. Its inhibition of hMAO-A provides valuable insights into monoamine metabolism and its implications in mental health. -
MAO Inhibitor
5-(2-Aminopropyl)indole is a potent monoamine oxidase (MAO) inhibitor that exhibits psychoactive properties. This compound demonstrates long-lasting stimulatory effects, making it relevant for studies investigating neurotransmitter modulation and related behavioral outcomes. Its applications include research into mood disorders, neurodegeneration, and the pharmacological mechanisms underlying psychoactive substances. -
MAO-A Inhibitor
Brofaromine hydrochloride is a selective inhibitor of monoamine oxidase A (MAO-A), as well as a 5-hydroxytryptamine (5-HT) uptake inhibitor. This compound exhibits significant antidepressant-like effects, demonstrated in preclinical models, including the social conflict test in rodents. It is primarily used in research examining mood disorders and the pharmacological modulation of serotonin levels. -
MAO-B Inhibitor
Atibeprone is a selective inhibitor of monoamine oxidase B (MAO-B), a key enzyme involved in the metabolism of neurotransmitters. This compound exhibits notable antidepressant activity, making it relevant for research into mood disorders and neurodegenerative diseases. Its specificity for MAO-B allows for the potential exploration of therapeutic strategies with reduced side effects compared to non-selective MAO inhibitors. -
MAO-B Inhibitor
MD 780236 free base is a selective inhibitor of monoamine oxidase B (MAO-B), acting as a competitive antagonist with regard to substrates such as phenylethylamine and 5-hydroxytryptamine (5-HT). By inhibiting MAO-B, this compound plays a crucial role in the modulation of neurotransmitter levels, making it valuable in research focused on neurodegenerative diseases and mood disorders. Its specificity for MAO-B provides a useful tool for investigating the biochemical pathways involving monoamine metabolism. -
MAO Inhibitor
Methyl piperate is an effective inhibitor of monoamine oxidase (MAO), showing significant inhibitory activity with an IC50 of 3.6 µM against MAO. It exhibits a preferential inhibitory effect on MAO-A (IC50 27.1 µM) compared to MAO-B (IC50 1.6 µM), demonstrating a bidirectional action. This compound is valuable in research related to mental health disorders, providing insights into therapeutic strategies targeting monoamine regulation. -
MAO Inhibitor
Caroxazone is a reversible inhibitor of monoamine oxidase (MAO), which is involved in the catabolism of neurotransmitters such as serotonin, norepinephrine, and dopamine. This compound exhibits significant antidepressant activity, making it valuable in the study of mood disorders. Caroxazone is utilized in research to explore mechanisms of depression and to evaluate potential therapeutic interventions targeting MAO. -
MAO Inhibitor
Acacetin 7-O-(6-O-malonylglucoside) is a reversible monoamine oxidase inhibitor targeting both monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) with IC50 values of 2.34 μM and 1.87 μM, respectively. This compound demonstrates significant inhibitory activity, making it a valuable tool in the research of neurodegenerative diseases and affective disorders. Its unique mechanism of action contributes to the understanding of monoamine neurotransmitter regulation in various neurological conditions. -
Monoamine Oxidase Inhibitor
Tranylcypromine is a potent monoamine oxidase (MAO) inhibitor that increases levels of neurotransmitters such as serotonin, norepinephrine, and dopamine in the brain. This compound is primarily used in the research of mood disorders and depression therapies, offering insights into the biochemical pathways involved in these conditions. Its specific mechanism of action makes it valuable for studying the modulation of neurotransmitter systems and the pharmacological effects of MAO inhibition. -
MAO Inhibitor
6,7-Dimethylisatin is a selective inhibitor of monoamine oxidase (MAO), exhibiting IC50 values of 20.3 μM for MAO-A and 6.74 μM for MAO-B. This compound holds potential for exploration in neurodegenerative diseases such as depression, Alzheimer's disease, and Parkinson's disease. Its role as a MAO inhibitor may contribute to understanding underlying mechanisms and developing therapeutic strategies in neurobiological research. -
Monoamine Oxidase Inhibitor
MAO-B-IN-1 is a selective inhibitor of monoamine oxidase B, targeting the enzyme responsible for the catabolism of neurotransmitters such as dopamine. This compound demonstrates significant potential for studying the role of monoamine oxidase B in neurological disorders, including Parkinson's disease and depression. MAO-B-IN-1 is valuable for researchers investigating the modulation of oxidative stress and neuroprotection in various neurobiological contexts. -
Keap1-Nrf2 PPI Inhibitor
Keap1-Nrf2-IN-9 is a selective inhibitor of the Keap1-Nrf2 protein-protein interaction (PPI) with a reported IC50 of 0.575 μM. This compound enhances the expression of Nrf2 target genes, including heme oxygenase 1 (Hmox1), glutathione S-transferase P (GstP), and the modulatory and catalytic subunits of glutamate-cysteine ligase (Gclc and Gclm). Keap1-Nrf2-IN-9 exhibits low cytotoxicity in ARPE19 cells, making it a valuable tool for studies focused on oxidative stress and cellular defense mechanisms. -
Tyrosinase/α-glucosidase Inhibitor
Pedalitin is a dual inhibitor of tyrosinase (IC50 = 0.28 mM) and α-glucosidase (IC50 = 0.29 mM). This compound demonstrates significant biological activity in the regulation of melanin production and glucose metabolism. Pedalitin is suitable for research applications exploring skin pigmentation disorders and metabolic diseases. -
Intermediate of SCD1/5 Inhibitor
1-Methyl-1H-pyrazole-3-carboxylic acid serves as an intermediate in the synthesis of SCD1 and SCD5 inhibitors. This compound is instrumental in investigating metabolic disorders and their mechanisms. Its role in the development of targeted therapies makes it a valuable reagent for chemical research in metabolic pathways. -
PPO Inhibitor
PPO-IN-1 is a potent inhibitor of protoporphyrinogen IX oxidase (PPO), exhibiting a Ki value of 2.5 nM. This compound serves as a valuable click chemistry reagent, featuring an alkyne group that enables it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions. Its primary biological activity makes it useful for studying pathways involving heme biosynthesis and investigating potential therapeutic applications in diseases related to PPO dysregulation. -
PYK Inhibitor
NCGC00188636 is a novel covalent inhibitor of pyruvate kinase (PYK). By blocking nucleotide binding at the active site, NCGC00188636 disrupts PYK activity, thereby influencing metabolic processes. This compound is suited for research into the metabolic pathways of various organisms and cell types, providing insights into cellular energy regulation and potential therapeutic targets. -
AR Degrader/CYP17A1 Inhibitor
YXG-158 is an orally active androgen receptor (AR) degrader and CYP17A1 inhibitor. It exhibits AR degradation activity with a DC50 value of 1.28 μM and inhibits CYP17A1 with an IC50 value of 100 nM. This compound is particularly relevant for research applications focused on enzalutamide-resistant prostate cancer, providing a valuable tool for investigating therapeutic strategies in this context. -
Carbonic anhydrase inhbitor
Indisulam (E7070) is a carbonic anhydrase inhbitor, is also a novel synthetic sulfon-amide that targets the G1 phase of the cell cycle. -
FTase inhibitor
FTI 276 is an inhibitor that inhibits farnesyltransferase (FTase) (IC50 = 0.5 nM). Inhibits H-Ras and K-Ras processing in whole cells (IC50 values are 0.1 and 10 μM respectively) and disrupts constitutive H-Ras-specific actvation of MAPK. Causes significant antiproliferative effects in human malignant glioma cells and many other tumor cell lines. -
GAPDH inhibitor
CGP 3466B maleate is an orally active glyceraldehyde-3-phosphate dehydrogenase (GAPDH) inhibitor. -
FAAH inhibitor
JNJ 1661010 is a selective and reversible inhibitor of fatty acid amide hydrolase (FAAH) (IC50 = 12nM). -
5-LPO inhibitor
ICI 211965 (ZM-211965) is a selective and orally potent 5-Lipoxygenase (5-LPO) inhibitor. -
DGAT1 inhibitor
Pradigastat (LCQ-908) is a diacylglycerol acyltransferase 1 (DGAT1) inhibitor. -
squalene synthetase inhibitor
YM-53601 free base is a squalene synthetase inhibitor which suppresses lipogenic biosynthesis and lipid secretion in rodents. -
NAMPT inhibitor
CHS-828 is a potent inhibitor of NAD+ biosynthesis enzyme NAMPT with IC50 <25 nM. -
FXa Inhibitor
Betrixaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. It is potent, orally active and highly selective for factor Xa, being selected from a group of similar compounds for its low hERG affinity. -
CYP3A4 inhibitor
PF 4981517 is a potent and selective inhibitor of CYP3A4 (IC50 values are 0.03, 17 and 70 μM for CYP3A4, CYP3A5 and CYP3A7 respectively). -
PDE 3/4 inhibitor
Zardaverine is a phosphodiesterase inhibitor, selective for PDE3 and 4 (IC50 values are 0.5 and 0.8 uM respectively).
